TORONTO STOCK EXCHANGE · CRDL
-1.24% · -$0.0234 · Vol 753.4K
Market closed · last close 4:00 PM ET · price as of 17:57:59 ET
Cardiol Therapeutics Inc

Cardiol Therapeutics Inc

Pharmaceuticals
$1.86
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
CRDL
Cardiol Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CRDL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CRDL catalysts
About Cardiol Therapeutics Inc
Pharmaceuticals
Listed since
2019
Employees
18
Country
CA

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.93
Day high
$1.93
Day low
$1.85
Previous close
$1.89
52W high
$1.96
-5.02% from high
52W low
$0.9260
90% of range
Market cap
$217.3M
EPS
$-0.3916
Beta
1.39
Shares out
116.8M
Volume
753.4K
0.62× rel vol
Avg volume
1.2M
VWAP
$1.88
Price history computed in-house
1W
+3.42%
1M
+57.76%
3M
+41.03%
1Y
+59.11%
YTD
+95.18%
SMA 50 $1.26 · above
SMA 200 $1.15 · above
52W position 90%

CRDL overview

Veridion Score
65
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CRDL.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CRDL Form 4 filings
Public disclosures

Congress activity in CRDL

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CRDL in the cached public ledger.

Federal contracts

CRDL contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CRDL in this window.
Lobbying spend

CRDL lobbying filings, year to date.

Registered lobbying filings matched to Cardiol Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CRDL in this window.
Loading news for CRDL
Analyst ratings
Sovereign unlock shows live analyst consensus for CRDL.
Options
Sovereign unlock shows live options positioning for CRDL.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.